Table 1.
Demographic and clinical characteristics of the patients at baseline*.
| Characteristic | Placebo (n = 9) | α-LA (n = 8) | Total (n = 17) |
|---|---|---|---|
| Median age (IQR) — yr | 63 (58–65) | 62.5 (59–67) | 63 (59–66) |
| Age category, no(%) | |||
| <60 y | 3 (33.33) | 3 (37.50) | 6 (35.29) |
| 60–70 y | 5 (55.56) | 4 (50.00) | 9 (52.94) |
| >70 y | 1 (11.11) | 1 (12.50) | 2 (11.76) |
| Male sex — no. (%) | 7 (77.78) | 6 (75.00) | 13 (76.47) |
| Oxygen-support category — no. (%) | |||
| Ambient air | 0 | 0 | 0 |
| Nasal or mask oxygen | 0 | 1 (12.50) | 1 (5.90) |
| High-flow oxgen or noninvasive ventilation | 3 (33.30) | 4 (50.00) | 7 (41.18) |
| invasive ventilation | 6 (66.67) | 3 (37.50) | 9 (52.94) |
| Coexisting conditions — no. (%) | |||
| Hypertension | 4 (44.44) | 4 (50.00) | 8 (47.06) |
| Diabetes | 3 (33.33) | 1 (12.50) | 4 (23.53) |
| coronary heart disease | 0 | 1 (12.50) | 1 (5.90) |
| Median laboratory values (IQR) | |||
| ALT(U/L) | 22.5 (16.50–43.50) | 45 (29.00–51.00) | 31.00 (18.00–51.00) |
| AST(U/L) | 39 (31.00–45.00) | 42 (34.00–62.00) | 40.00 (32.50–48.50) |
| Serum creatinine (umol/L) | 105.9 (64.55–247.45) | 62.8 (58.1–268) | 85.70 (58.10–266.70) |
| PT(s) | 13.8 (12.40–15.50) | 13.7 (11.70–29.00) | 7.83 (4.25–12.62) |
| APTT(s) | 33.1 (26.00–35.10) | 29.7 (22.70–44.10) | 13.75 (12.15–23.55) |
| D-dimer | 4.84 (4.25–9.62) | 10.23 (6.49–19.77) | 32.70 (23.35–42.26) |
| Blood routine | |||
| RBC (10∧12) | 3.07 ± 0.67 | 3.49 ± 0.69 | 3.25 ± 0.69 |
| WBC (10∧12) | 13.60 ± 5.21 | 8.84 ± 5.58 | 11.52 ± 5.73 |
| Plt (10∧9) | 227.33 ± 119.64 | 201.00 ± 90.11 | 215.81 ± 105.19 |
| SOFA | 4.33 ± 2.00 | 3.75 ± 2.05 | 4.06 ± 1.98 |
*
Plus-minus values are means ± SD. There were no significant differences between the groups in any of the characteristics listed in this table. ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; PT, prothrombin time; APTT, activated partial thromboplastin time; RBC, red blood cell; WBC, white blood cell; Plt, platelet; SOFA, sequential organ failure assessment.